Kailera Therapeutics, Inc.
KLRANasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annualNo structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Enrolling By Invitationreadout ~2027-05Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
- Phase 2Recruitingreadout ~2027-07-07Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
- Phase 3Recruitingreadout ~2028-02-28Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Phase 3Recruitingreadout ~2028-03-20Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
- Phase 3Recruitingreadout ~2028-03-27Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Bcls Fund Iv Investments, L.P.Activist (13D)Apr 23, 2026
- Bcpe Perseus Investor, LpActivist (13D)Apr 23, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Rtw Investments, Lp10% owner | Apr 20, 2026 | Conversion | 10.3M | — |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd.10% owner | Apr 20, 2026 | Conversion | 9.5M | — |
| Bain Capital Investors Llc10% owner | Apr 20, 2026 | Conversion | 17.9M | — |
| Koppel AdamDirector | Apr 20, 2026 | Conversion | 16.9M | — |
| Bain Capital Life Sciences Investors, Llc10% owner | Apr 20, 2026 | Conversion | 16.9M | — |
| Kaplan Andrew T.Director | Apr 20, 2026 | Conversion | 17.9M | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.7M | 5.9 | +35.9% |
| Apr 30, 2026 | 2.0M | 1.1 | +100.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recentEvents the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QMay 26, 2026
- 8-KMay 26, 2026
- SCHEDULE 13DApr 23, 2026
- SCHEDULE 13DApr 23, 2026
- 4Apr 22, 2026
- 4OWNERSHIP DOCUMENTApr 22, 2026
- 4Apr 20, 2026
- 4Apr 20, 2026
- 4Apr 20, 2026
- 4Apr 20, 2026
- 4Apr 20, 2026
- 4Apr 20, 2026
- 4Apr 20, 2026
- 4Apr 20, 2026
- 4Apr 20, 2026